Aside from cancer, stroke has long been the number one cause of death in Korea, followed by heart disease. Last year, our gov ernment reported that this order was reversed, due primarily to a decrease in stroke mortality ( Figure 1 ). The change is strik ing; ten years ago (in 2002), stroke mortality was about two times higher than that of heart disease (77 per 100,000 vs. 36.9 per 100,000, respectively) while in 2012, the mortality rate due to heart disease and stroke was 52.5 and 51.1 per 100,000 peo ple, respectively.
One of the important reasons for the rapid decline in stroke mortality is the improved quality of stroke care during the last 10 years; public awareness of stroke symptoms improved, the proportion of patients visiting hospitals within 3 hours increas ed, and door to needle time shortened, 1 due in part to the wide spread use of a computerized inhospital alert system. Year risk factor control, there is no evidence of decreasing incidence of stroke in Korea, probably related with a rapidly increasing aged population. In this sense, stroke's stepping down to the 3rd most prominent cause of death is not news to toast. In fact, more research should be conducted to find ways to ameliorate the ev erincreasing burden of stroke, both from academia and the gov ernment.
The recent changes shown in Korea have already been ob served in Japan, and are currently shared by many other Asian countries such as urban China, Taiwan, and Hong Kong, as in troduced in the recent editions of the Journal of Stroke (JOS). I believe that it is time to focus more on primary prevention by promoting healthy life style changes, (e.g., low salt intake, regu lar physical exercise, and stopping smoking). This will help de crease stroke incidence and unacceptably high stroke burden in Asia. Needless to say, Asian governments should play a bigger role than before.
One of the missions of JOS is to address these Asian issues worldwide. In this volume, you can read with interest about stroke epidemiology in Taiwan, genetic abnormalities in moy amoya disease, and an argument that new oral anticoagulants may be particularly useful for Asian stroke patients, on which Dr. Diener kindly sent his comments. I hope you enjoy reading them.
